Breaking News Instant updates and real-time market news.

PRTA

Prothena

$14.29

0.43 (3.10%)

16:29
08/07/18
08/07
16:29
08/07/18
16:29

Prothena reports Q2 EPS ($1.50), consensus ($1.13)

As of June 30, 2018, Prothena had $490.3 million in cash, cash equivalents and restricted cash.

PRTA Prothena
$14.29

0.43 (3.10%)

06/15/18
CANT
06/15/18
NO CHANGE
Target $18
CANT
Overweight
Prothena price target raised to $18 from $14 at Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner raised his price target for Prothena to $18 citing his analysis of the potential value of the company's drug discovery platform and management's recently announced restructuring plan. The analyst reiterates a Overweight rating on the shares.
05/21/18
LEHM
05/21/18
DOWNGRADE
Target $12
LEHM
Underweight
Prothena downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Geoffrey Meacham downgraded Prothena to Underweight and cut his price target for the shares to $12 from $14. The analyst sees limited value creating pipeline events in the near-term after the company discontinued development of NEOD001, an investigational antibody that was being evaluated for the treatment of AL amyloidosis. He believes it remains too early to assign much value to PRX002 in Parkinson's or PRX004 in ATTR amyloidosis.
04/24/18
04/24/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alcoa (AA) downgraded to Neutral from Buy at Citi with analyst Alexander Hacking saying the stock is up 60% year-over-year. 2. Dynagas LNG (DLNG) downgraded to Underperform from Market Perform at Wells Fargo with analyst Michael Webber saying another distribution cut is possible given expensive dropdowns from the company's private sponsor. 3. Skyworks (SWKS) downgraded to Neutral from Buy at Mizuho with analyst Vijay Rakesh saying the effects of a maturing handset cycle could start to impact the RF suppliers. 4. Prothena (PRTA) downgraded to Neutral from Buy at BTIG and to Perform from Outperform at Oppenheimer. 5. Donegal Group (DGICA) downgraded to Neutral from Outperform at Boenning & Scattergood. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/24/18
BTIG
04/24/18
DOWNGRADE
BTIG
Neutral
Prothena downgraded to Neutral from Buy at BTIG
BTIG analyst Robert Hazlett downgraded Prothena to Neutral from Buy after the PRONTO study read out negatively, which led directly to the discontinuation of the entire NEOD001 program. Despite noting that the company has programs "that appear quite promising," Hazlett prefers to move to the sidelines with important catalysts now farther out, with a readout for its 002 program in Parkinson's due in 2020.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.